Study of the non-covalent interaction between amyloid-β-peptide and melatonin using electrospray ionization mass spectrometry

Journal of Mass Spectrometry

Volumn 40, Issue 2, 2005, Pages 182-192

  Bazoti, Fotini M ^a,b   Tsarbopoulos, Anthony ^a,b   Markides, Karin E ^c   Bergquist, Jonas ^c  

^a Goulandris Natural History Museum   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Amyloid peptide; Electrospray ionization mass spectrometry; Melatonin; Non covalent complexes

Indexed keywords

ANTIOXIDANTS; COMPLEXATION; FOURIER TRANSFORMS; IMMUNOLOGY; IONIZATION; MEDICAL PROBLEMS; NEUROLOGY; PH EFFECTS; PROTEINS;

ALZHEIMER'S DISEASE (AD); NEURODEGENERATION; NON-COVALENT INTERACTIONS; PEPTIDE FRAGMENTS;

MASS SPECTROMETRY;

AMYLOID BETA PROTEIN; ANTIOXIDANT; FREE RADICAL; MELATONIN; PEPTIDE FRAGMENT; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BINDING SITE; CONCENTRATION (PARAMETERS); ELECTRIC POTENTIAL; ELECTROSPRAY MASS SPECTROMETRY; HORMONE PROTEIN COMPLEX; IMMUNE RESPONSE; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MOLECULAR STABILITY; NERVE DEGENERATION; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; RISK ASSESSMENT; TIME;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; BINDING SITES; CHYMOTRYPSIN; MELATONIN; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN INTERACTION MAPPING; SERINE ENDOPEPTIDASES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS; TRYPSIN;

EID: 14744278224     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.738     Document Type: Article

References (47)

1. Ganguly AK, Pramanik BN, Chen G, Tsarbopoulos A. Detection of noncovalent complexes by electrospray ionization mass spectrometry. In Applied Electrospray Mass Spectrometry, Pramanik BN, Ganguly AK, Gross ML (eds). Marcel Dekker: New York, 2002; 361.
2. Pramanik BN, Bartner PL, Mirza UA, Liu YH, Ganguly AK. Electrospray Ionization Mass Spectrometry for the Study of Non-covalent Complexes: an Emerging Technology. J. Mass Spectrom. 1998; 33: 911.
3. Heininger K. A Unifying Hypothesis of Alzheimer's Disease. II. Pathophysiological Processes. Hum. Psychopharmacol. Clin. Exp. 1999; 14: 525.
4. Clippingdale AB, Wade JD, Barrow CJ. The Amyloid-β Peptide and its Role in Alzheimer's Disease. J. Pept. Sci. 2001; 7: 227.
5. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 1999; 266: 1101.
6. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis. J. Biol. Chem. 1998; 273: 12817.
7. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J. Caspace-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98.
8. Stadtman ER. Protein Oxidation in Aging and Age-Related Diseases. Ann. N. Y. Acad. Sci. 2001; 928: 22.
9. Markesbery WR, Carney JM. Oxidative Alterations in Alzheimer's Disease. Brain Pathol. 1999; 9: 133.
10. Head E, Garzon-Rodriguez, W, Johnson, JK, Lott IT, Cotman CW, Glabe C. Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome. Neurobiol. Dis. 2001; 8: 792.
11. Heininger K. A unifying hypothesis of Alzheimer's disease. I. Ageing sets the stage. Hum. Psychopharmacol. Clin. Exp. 1999; 14: 363.
12. Davies KJA. Degradation of oxidized proteins by the 20S proteasome. Biochimie 2001; 83: 301.
13. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE. Comparative Analysis of Amyloid-β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains. J. Biol. Chem. 2001; 276: 12991.
14. Levine RL, Mosoni L, Berlett BS, Stadtman ER. Methionine residues as endogenous antioxidants in proteins. Proc. Natl. Acad. Sci. USA 1996; 93: 15036.
15. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glade CG, Cotman CW. Structure-Activity Analyses of β-Amyloid Peptides: Contributions of the β25-35 Region to Aggregation and Neurotoxicity. J. Neurochem. 1995; 64: 253.
16. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 1994; 67: 1216.
17. Seilheimer B, Bohrmann B, Bondoli L, Müller F, Stüber D, Döbeli H. The Toxicity of the Alzheimer's β-Amyloid Peptide Correlates with a Dinstict Fiber Morphology. J. Struct. Biol. 1997; 119: 59.
18. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. USA 1995; 92: 1989.
19. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994; 91: 3270.
20. Liu RY, Zhou JN, van Heerikhuize JJ, Hofman MA, Swaab DF. Decreased Melatonin Levels in Postmortem Cerebrospinal Fluid in Relation to Aging, Alzheimer's Disease, and Apolipoprotein E-ε4/4 Genotype. J. Clin. Endocrinol. Metab. 1999; 84: 323.
21. Maurizi CP. Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med. Hypotheses 2001; 57: 156.
22. Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, Brockhaus M, Muller-Spahn F. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J. Pineal Res. 2001; 31: 320.
23. Savaskan E. Melatonin in Aging and Neurodegeneration. Drug Dev. Res. 2002; 56: 482.
24. Song W, Lahiri DK. Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendrocrine cell line PC12. J. Mol. Neurosci. 1997; 9: 75.
25. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Robakis NK. Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide. J. Neurosci. 1997; 17: 1683.
26. Cozzi B, Rollag MD. The protein-phosphatase inhibitor okadaic acid mimics MSH-induced and melatonin-reversible melanosome dispersion in Xenopus laevis melanophores. Pigment Cell Res. 1992; 5: 148.
27. Matsubara E, Shoji M, Murakami T, Kawarabayashi T, Abe K. Alzheimer's disease and melatonin. International Congress Series. Int. Congr. Ser. 2003; 1252: 395.
28. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: impications for Alzheimer's disease. J. Neural Transmission 2000; 107: 203.
29. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry. 1996; 35: 13568.
30. Lorenzo A, Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 1994; 91: 12243.
31. Carter MD, Weaver DF. Ab initio molecular modeling of imidazolium interaction with 5-hydroxy- and 5-methoxyindole: implications for melatonin-based inhibition of Alzheimer β-amyloid fibril formation. J. Mol. Struct. (Theochem) 2003; 626: 279.
32. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J. Inhibition of Alzheimer β-Fibrillogenesis by Melatonin. J. Biol. Chem. 1998; 273: 7185.
33. Skribanek Z, Baláspiri L, Mák M. Interaction Between synthetic amyloid-β-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 2001; 36: 1226.
34. Biemann K, Martin SA. Mass spectrometric determination of the amino acid sequence of peptides and proteins. Mass Spectrom. Rev. 1987; 6: 1.
35. Loo JA. Electrospray ionization mass spectrometry: a technology for studying noncovalent macromolecular complexes. Int. J. Mass Spectrom. 2000; 200: 175.
36. Palmblad M, Håkansson K, Håkansson P, Feng XD, Cooper HJ, Giannakopulos AE, Green PS, Derrick PJ. A 9.4 T Fourier transform ion cyclotron resonance mass spectrometer: descroption and performance. Eur. J. Mass Spectrom. 2000; 6: 267.
37. Nilsson S, Wetterhall M, Bergquist J, Nyholm L, Markides KE. A simple and robust conductive graphite coating for sheathless electrospray emitters used in capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 2001; 15: 1997.
38. Huang EC, Pramanik BN, Tsarbopoulos A, Reichert P, Ganguly AK, Trotta PP, Nagabhushan TL, Covey TR. Application of Electrospray Mass Spectrometry in Probing Protein-Protein and Protein-Ligand Noncovalent Interactions. J. Am. Soc. Mass Spectrom. 1993; 4: 624.
39. Shen CL, Murphy RM. Solvent effects on self-assembly of beta-amyloid peptide. Biophys. J. 1995; 69: 640.
40. Ganguly AK, Pramanik BN, Huang E, Tsarbopoulos A, Girijavallabhan VM, Liberles S. Studies of the Ras-GDP and Ras-GTP Noncovalent Complexes by Electrospray Mass Spectrometry. Tetrahedron 1993; 49: 7985.
41. Palmblad M, Westlind-Danielsson A, Bergquist J. Oxidation of Methionine 35 Attenuates Formation of Amyloid β-peptide 1-40 Oligomers. J. Biol. Chem. 2002; 227: 19506.
42. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of Amyloid Fibril-forming Proteins. J. Biol. Chem. 2001; 276: 12945.
43. Tjernberg LO, Callaway DJE, Tjernberg A, Hahne S, Lilliehöök K, Terenius L, Thyberg J, Nordstedt C. A Molecular Model of Alzheimer Amyloid β-Peptide Fibril Formation. J. Biol. Chem. 1999; 274: 12619.
44. Tjernberg LO, Näslund L, Lindqvist F, Johansson J, Karlström AR, Thyberg J, Terenius L, Nordstedt C. Arrest of β-Amyloid Fibril Formation by a Pentapeptide Ligand. J. Biol. Chem. 1996; 271: 8545.
45. Walsh DM, Lomakin A, Benedek GB, Condron MN, Teplow DB. Amyloid β-Protein Fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 1997; 272: 22364.
46. Penke B, Datki Z, Hetényi C, Molnár Z, Lengyel I, Soós K, Zarándi M. Molecular pathomechanisms of Alzheimer's disease. J. Mol. Struct. 2003; 666-667: 507.
47. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappolla MA. Potent Neuroprotective Properties against the Alzheimer β-Amyloid by an Endogenous Melatonin-related Indole Structure, Indole-3-propionic Acid. J. Biol. Chem. 1999; 274: 21937.